cell-derived monovalent H1N1 swine-origin influenza vaccine

The cell-derived monovalent H1N1 swine-origin influenza vaccine, marketed under the brand name Celtura, is an inactivated, cell culture-derived, monovalent subunit influenza virus vaccine developed to prevent pandemic influenza caused by the swine-origin A/H1N1 virus. Developed by Novartis Vaccines and Diagnostics (with the influenza vaccine portfolio later acquired by Seqirus, a CSL company), the vaccine contains hemagglutinin (HA) and neuraminidase surface antigens derived from the A/California/7/2009 (H1N1)v-like strain (specifically the X-179A reassortant). Unlike traditional egg-based vaccines, Celtura is produced in Madin-Darby Canine Kidney (MDCK) cell culture, offering a faster and more scalable manufacturing process during a pandemic. It is formulated with the MF59 oil-in-water emulsion adjuvant to enhance immunogenicity and enable antigen dose sparing, allowing for a robust immune response even at low antigen doses (3.75 µg). The vaccine was approved in several European countries, including Germany and Switzerland, during the 2009 H1N1 influenza pandemic.

Brand names

Celtura

Other names

cell-culture-derived monovalent H1N1 swine-origin influenza vaccineMDCK cell-derived H1N1 influenza vaccineMF59-adjuvanted cell-derived monovalent H1N1 swine-origin influenza vaccineMF-59-adjuvanted cell-derived monovalent H1N1 swine-origin influenza vaccineMF 59-adjuvanted cell-derived monovalent H1N1 swine-origin influenza vaccine